1. Histology or cytology confirmed patients with stage IV squamous cell carcinoma of IASLC TNM (8th edition);
2. Patients have not previously received first-line anti-tumor systemic therapy for advanced lung cancer;
3. At least one measurable lesion according to the irRECIST 1.1 standard;
4. Physical condition and organ function allow for systemic antitumor therapy, including standard chemotherapy and immunotherapy;
5. Age ≥ 18 years at the time of signing the informed consent form;
6. Estimated survival≥ 3 months;
7. Patients can follow the planned schedule and actively cooperate in returning to the hospital for regular clinical follow-up and necessary treatment;
8. It can provide the clinical data required for research and is willing to use the test data for further scientific research and commercial product development.